Skip to main content

Compare Stocks

Date Range: 

 CRISPR TherapeuticsPacific Biosciences of CaliforniaInvitae
SymbolNASDAQ:CRSPNASDAQ:PACBNYSE:NVTA
Price Information
Current Price$109.22$23.39$27.31
52 Week RangeBuyBuyBuy
MarketRank™
Overall Score1.71.61.6
Analysis Score4.33.43.3
Community Score2.72.82.5
Dividend Score0.00.00.0
Ownership Score1.71.71.7
Earnings & Valuation Score0.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuy
Consensus Price Target$160.88$43.50$46.17
% Upside from Price Target47.29% upside85.98% upside69.05% upside
Trade Information
Market Cap$8.28 billion$4.64 billion$5.46 billion
Beta2.371.322.11
Average Volume2,062,0734,396,2284,383,463
Sales & Book Value
Annual Revenue$289.59 million$90.89 million$216.82 million
Price / Sales28.5851.0525.17
Cashflow$0.71 per shareN/AN/A
Price / Cash154.11N/AN/A
Book Value$17.02 per share$0.36 per share$3.93 per share
Price / Book6.4264.976.95
Profitability
Net Income$66.86 million$-84,130,000.00$-241,960,000.00
EPS$1.17($0.55)($2.28)
Trailing P/E RatioN/AN/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/A
Net Margins-273.10%-57.25%-183.50%
Return on Equity (ROE)-20.72%-101.30%-81.19%
Return on Assets (ROA)-18.35%-32.33%-37.28%
Dividend
Annual PayoutN/AN/AN/A
Dividend YieldN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/A
Payout RatioN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.68%
Current Ratio16.53%1.84%4.09%
Quick Ratio16.53%1.72%4.09%
Ownership Information
Institutional Ownership Percentage66.43%84.85%78.60%
Insider Ownership Percentage17.10%11.60%2.90%
Miscellaneous
Employees4104122,100
Shares Outstanding75.77 million198.37 million199.84 million
Next Earnings Date7/26/2021 (Estimated)8/2/2021 (Estimated)8/3/2021 (Estimated)
OptionableOptionableOptionableOptionable
SourceHeadline
Top Five Articles on GenomeWeb Last Week: Singular Genomics, Invitae, COVID-19, and More - GenomeWebTop Five Articles on GenomeWeb Last Week: Singular Genomics, Invitae, COVID-19, and More - GenomeWeb
genomeweb.com - May 17 at 1:02 PM
Heres What Stood Out With Invitaes Q1 Results - The Motley FoolHere's What Stood Out With Invitae's Q1 Results - The Motley Fool
fool.com - May 13 at 9:25 AM
Heres What Stood Out With Invitaes Q1 ResultsHere's What Stood Out With Invitae's Q1 Results
finance.yahoo.com - May 13 at 9:25 AM
Invitae (NYSE:NVTA) Price Target Lowered to $41.00 at Morgan StanleyInvitae (NYSE:NVTA) Price Target Lowered to $41.00 at Morgan Stanley
americanbankingnews.com - May 12 at 9:14 AM
Morgan Stanley Cuts Invitae (NYSE:NVTA) Price Target to $41.00Morgan Stanley Cuts Invitae (NYSE:NVTA) Price Target to $41.00
marketbeat.com - May 12 at 8:29 AM
Invitae (NYSE:NVTA) Trading 2.3% Higher Invitae (NYSE:NVTA) Trading 2.3% Higher
americanbankingnews.com - May 11 at 11:39 AM
Invitae (NYSE:NVTA) Given New $50.00 Price Target at SVB LeerinkInvitae (NYSE:NVTA) Given New $50.00 Price Target at SVB Leerink
americanbankingnews.com - May 11 at 8:40 AM
Natera Cancer Test Infringes Invitae Patent, Suit Alleges - Law360Natera Cancer Test Infringes Invitae Patent, Suit Alleges - Law360
law360.com - May 11 at 4:38 AM
Is Invitae Corp (NVTA) a Stock to Watch After Losing -16.67% This Week? - InvestorsObserverIs Invitae Corp (NVTA) a Stock to Watch After Losing -16.67% This Week? - InvestorsObserver
investorsobserver.com - May 10 at 1:08 PM
Relative Strength Alert For Invitae - NasdaqRelative Strength Alert For Invitae - Nasdaq
nasdaq.com - May 10 at 1:08 PM
Invitae Sues Natera Alleging Infringement of Patent on DNA Sequencing Assembly Technique - GenomeWebInvitae Sues Natera Alleging Infringement of Patent on DNA Sequencing Assembly Technique - GenomeWeb
genomeweb.com - May 10 at 1:08 PM
-$0.71 EPS Expected for Invitae Co. (NYSE:NVTA) This Quarter-$0.71 EPS Expected for Invitae Co. (NYSE:NVTA) This Quarter
americanbankingnews.com - May 8 at 9:14 AM
Invitae (NVTA) Outpaces Stock Market Gains: What You Should Know - NasdaqInvitae (NVTA) Outpaces Stock Market Gains: What You Should Know - Nasdaq
nasdaq.com - May 7 at 8:23 PM
Invitae (NVTA) Outpaces Stock Market Gains: What You Should KnowInvitae (NVTA) Outpaces Stock Market Gains: What You Should Know
finance.yahoo.com - May 7 at 8:23 PM
Q2 2021 EPS Estimates for Invitae Co. Decreased by Analyst (NYSE:NVTA)Q2 2021 EPS Estimates for Invitae Co. Decreased by Analyst (NYSE:NVTA)
americanbankingnews.com - May 7 at 10:38 AM
Best Places to Work 2021: Invitae keeps a focus on the core elements of their culture amid changes - San Francisco Business Times - San Francisco Business TimesBest Places to Work 2021: Invitae keeps a focus on the core elements of their culture amid changes - San Francisco Business Times - San Francisco Business Times
bizjournals.com - May 6 at 9:44 PM
Invitae (NYSE:NVTA) Given New $41.00 Price Target at Morgan StanleyInvitae (NYSE:NVTA) Given New $41.00 Price Target at Morgan Stanley
marketbeat.com - May 6 at 11:37 AM
Invitae (NYSE:NVTA) Price Target Cut to $41.00 by Analysts at Morgan StanleyInvitae (NYSE:NVTA) Price Target Cut to $41.00 by Analysts at Morgan Stanley
americanbankingnews.com - May 6 at 9:04 AM
Invitae Shares Trading Lower As Q1 Earnings Lag Estimates, Contracting Margins - Yahoo FinanceInvitae Shares Trading Lower As Q1 Earnings Lag Estimates, Contracting Margins - Yahoo Finance
finance.yahoo.com - May 6 at 4:13 AM
Invitae (NYSE:NVTA) Issues Quarterly  Earnings ResultsInvitae (NYSE:NVTA) Issues Quarterly Earnings Results
americanbankingnews.com - May 5 at 11:58 PM
Invitae Stock Gives Every Indication Of Being Significantly Overvalued - Yahoo FinanceInvitae Stock Gives Every Indication Of Being Significantly Overvalued - Yahoo Finance
finance.yahoo.com - May 5 at 11:13 PM
SVB Leerink Cuts Invitae (NYSE:NVTA) Price Target to $50.00SVB Leerink Cuts Invitae (NYSE:NVTA) Price Target to $50.00
americanbankingnews.com - May 5 at 3:24 PM
Invitae (NVTA) Q1 2021 Earnings Call Transcript - Motley FoolInvitae (NVTA) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - May 5 at 1:07 PM
Invitae: Q1 Earnings Snapshot - Modesto BeeInvitae: Q1 Earnings Snapshot - Modesto Bee
modbee.com - May 5 at 1:07 PM
Invitae Shares Trading Lower As Q1 Earnings Lag Estimates, Contracting MarginsInvitae Shares Trading Lower As Q1 Earnings Lag Estimates, Contracting Margins
finance.yahoo.com - May 5 at 1:07 PM
Invitae (NYSE:NVTA)  Shares Down 8.5%  on Disappointing EarningsInvitae (NYSE:NVTA) Shares Down 8.5% on Disappointing Earnings
americanbankingnews.com - May 5 at 11:56 AM
Heres Why Invitaes Q1 Revenue Soared 61% - Motley FoolHere's Why Invitae's Q1 Revenue Soared 61% - Motley Fool
fool.com - May 5 at 8:06 AM
3 Groundbreaking Genomics Stocks to Buy Now (NVTA)3 Groundbreaking Genomics Stocks to Buy Now (NVTA)
marketbeat.com - January 8 at 6:58 PM
DateCompanyBrokerageAction
5/13/2021CRISPR TherapeuticsEvercore ISIUpgrade
4/27/2021CRISPR TherapeuticsJefferies Financial GroupUpgrade
4/27/2021CRISPR TherapeuticsBarclaysBoost Price Target
3/10/2021CRISPR TherapeuticsJMP SecuritiesInitiated Coverage
2/17/2021CRISPR TherapeuticsThe Goldman Sachs GroupLower Price Target
2/17/2021CRISPR TherapeuticsOppenheimerBoost Price Target
2/17/2021CRISPR TherapeuticsChardan CapitalBoost Price Target
2/17/2021CRISPR TherapeuticsNeedham & Company LLCReiterated Rating
1/12/2021CRISPR TherapeuticsTruistBoost Price Target
12/10/2020CRISPR TherapeuticsPiper SandlerBoost Price Target
12/7/2020CRISPR TherapeuticsStifel NicolausBoost Price Target
12/7/2020CRISPR TherapeuticsCanaccord GenuityBoost Price Target
12/7/2020CRISPR TherapeuticsRoth CapitalBoost Price Target
12/7/2020CRISPR TherapeuticsWells Fargo & CompanyDowngrade
10/30/2020CRISPR TherapeuticsRaymond JamesReiterated Rating
2/12/2021Pacific Biosciences of CaliforniaMorgan StanleyBoost Price Target
2/11/2021Pacific Biosciences of CaliforniaCantor FitzgeraldBoost Price Target
10/2/2020Pacific Biosciences of CaliforniaJPMorgan Chase & Co.Upgrade
12/18/2019Pacific Biosciences of CaliforniaPiper Jaffray CompaniesReiterated Rating
4/2/2019Pacific Biosciences of CaliforniaStephensDowngrade
1/4/2019Pacific Biosciences of CaliforniaCowenDowngrade
5/11/2021InvitaeSVB LeerinkLower Price Target
2/25/2021InvitaeLADENBURG THALM/SH SHUpgrade
7/1/2020InvitaeBenchmarkDowngrade
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.